Opexa Therapeutics Inc. (NASDAQ:OPXA) shares traded up 5.1% during trading on Friday . The stock traded as high as $4.73 and last traded at $4.50, with a volume of 176,003 shares traded. The stock had previously closed at $4.28.

Several research analysts have commented on the company. Maxim Group reaffirmed a “buy” rating on shares of Opexa Therapeutics in a report on Friday, June 10th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Opexa Therapeutics in a report on Sunday, July 3rd.

The firm has a 50-day moving average of $3.72 and a 200-day moving average of $2.61. The firm’s market capitalization is $31.14 million.

Opexa Therapeutics (NASDAQ:OPXA) last posted its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.04. During the same quarter in the previous year, the business earned ($0.96) EPS. On average, equities research analysts predict that Opexa Therapeutics Inc. will post ($0.99) earnings per share for the current year.

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company’s T-cell technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.